SAR422459 not checked

Sanofi

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Stargardt's Disease
Main trialPhase 2
“Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity”In the company’s words, NCT01736592 on ClinicalTrials.gov

Other drugs for Stargardt's Disease

All 11 drugs for Stargardt's Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 29 Aug 2033 Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Phase 1/2Terminated 16 Aug 2019 Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SAR422459

Following is part of Solo: you see every change to SAR422459 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in